1. Home
  2. AVBH vs HELP Comparison

AVBH vs HELP Comparison

Compare AVBH & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVBH

Avidbank Holdings Inc.

HOLD

Current Price

$30.42

Market Cap

330.3M

Sector

N/A

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$5.19

Market Cap

279.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVBH
HELP
Founded
2003
N/A
Country
United States
Canada
Employees
151
50
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.3M
279.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AVBH
HELP
Price
$30.42
$5.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$34.33
$51.50
AVG Volume (30 Days)
56.0K
1.4M
Earning Date
04-27-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$350.70
N/A
Revenue Next Year
$11.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.95
$4.29
52 Week High
$31.61
$8.55

Technical Indicators

Market Signals
Indicator
AVBH
HELP
Relative Strength Index (RSI) 67.17 46.31
Support Level $29.23 $4.55
Resistance Level $31.41 $8.55
Average True Range (ATR) 0.64 0.44
MACD 0.07 0.04
Stochastic Oscillator 67.90 24.85

Price Performance

Historical Comparison
AVBH
HELP

About AVBH Avidbank Holdings Inc.

Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: